FAVIPIRAVIR: A PRIMARY TREATMENT OF COVID-19
Shubham S. Shinde* and Rutuja S. Babar
ABSTRACT
Favipiravir generally comes under antiviral activity. Favipiravir shows pharmacokinetic and pharmacodynamic activity. The mechanism depends on RNA dependent. And it was effective against different viruses. Favipiravir is available in different combinations such as Hydro chloroquinoline, Oseltamivir, Theophylline, Raloxifene, Hydralazine, etc. The article grants a comparative duty of issued logical assessments either as separate drug or in combinations so that it is supportive for research professors worldwide. Favipiravir use in the treatment of not only COVID-19 but also in Nipah, Ebola, Influenza and other kinds of virus treatment also. The author here mentions drug interaction and dose level with also cover different parameters. Dose of favipiravir may cause a problem in uric acid. And also, wish to present more data of favipiravir due to current COVID-19 Situation.
Keywords: Favipiravir, COVID-19, Influenza, Nipah, Ebola.
[Full Text Article]